The DOI matches its Crossref record.
Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori
Abstract
Helicobacter pylori eradication rates by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin at standard doses depend on bacterial susceptibility to clarithromycin and patient CYP2C19 genotypes. We examined the usefulness of a personalized therapy for H. pylori infection based on these factors as determined by genetic testing. First, optimal lansoprazole dosing schedules that would achieve sufficient acid inhibition to allow H. pylori eradication therapy in each of different CYP2C19 genotype groups were determined by a 24-h intragastric pH monitoring. Next, 300 H. pylori-positive patients were randomly assigned to the standard regimen group (lansoprazole 30 mg twice daily (b.i.d.)), clarithromycin 400 mg b.i.d., and amoxicillin 750 mg b.i.d. for 1 week) or the tailored regimen group based on CYP2C19 status and bacterial susceptibility to clarithromycin assessed by genetic testing. Patients with failure of eradication underwent the second-line regimen. The per-patient cost required for successful eradication was calculated for each of the groups. In the first-line therapy, the intention-to-treat eradication rate in the tailored regimen group was 96.0% (95% CI=91.5-98.2%, 144/150), significantly higher than that in the standard regimen group (70.0%: 95% CI=62.2-77.2%, 105/150) (P<0.001). Final costs per successful eradication in the tailored and standard regimen groups were $669 and $657, respectively. In conclusion, the pharmacogenomics-based tailored treatment for H. pylori infection allowed a higher eradication rate by the initial treatment without an increase of the final per-patient cost for successful eradication. However, the precise cost-effectiveness of this strategy remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Helicobacter pylori treatment in the era of increasing antibiotic resistance
Graham, D. Y., & Fischbach, L. (2010) · Gut · doi:10.1136/gut.2009.192757 · Cited by 1,028
New concepts of resistance in the treatment of Helicobacter pylori infections
Graham, D. Y., & Shiotani, A. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1138 · Cited by 359
Lima, J. J., Thomas, C. D., Barbarino, J., Desta, Z., Van Driest, S. L., El Rouby, N., Johnson, J. A., Cavallari, L. H., Shakhnovich, V., Thacker, D. L., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2015 · Cited by 315
Self-citation
Metadata
- Authors
- Furuta, T., Shirai, N., Kodaira, M., Sugimoto, M., Nogaki, A., Kuriyama, S., Iwaizumi, M., Yamade, M., Terakawa, I., Ohashi, K., Ishizaki, T., & Hishida, A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-01-10
- Volume
- 81
- Issue
- 4
- Pages
- 521-528
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2050132242
- Cited by
- 187
- References
- 0
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori. https://app.cochat.ai/papers/10.1038/sj.clpt.6100043
- The paper
- Furuta, T., Shirai, N., Kodaira, M., Sugimoto, M., Nogaki, A., Kuriyama, S., Iwaizumi, M., Yamade, M., Terakawa, I., Ohashi, K., Ishizaki, T., & Hishida, A. (2007). Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/sj.clpt.6100043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.